Tyra Announces $400M Pricing of Common Stock and Pre-Funded Warrants

Tyra priced an offering of 9.08M common shares at $22.03 each and 9.08M pre-funded warrants at $22.029 each, expected to raise $400M. Underwriters bought at $20.7082 per unit. Proceeds will support drug development and corporate purposes, according to the company.

Original reporting
Published Sep 15, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tyra Announces $400M Pricing of Common Stock and Pre-Funded Warrants — source image
Decision brief

The 30-second read

$TYRABullishHigh
01

Why it matters

The raise strengthens the balance sheet and may accelerate clinical development, influencing investor sentiment.

02

Market read

Primary disclosure of a sizable capital raise for a small‑cap biotech, offering a clear trading catalyst.

03

What to watch

Potential covenant restrictions on the use of proceeds and market appetite for biotech equity.

Relevance 9/10Novelty 9/10Timing: today

Background

Tyra Biosciences filed an 8‑K reporting a $400M equity offering to fund its dabogratinib program and other initiatives.

Company-level read

Ticker impact

$TYRABullishHigh confidence
Context

Tyra Biosciences announced a $400M underwritten offering of common stock and pre‑funded warrants.

Expected impact

Potential short‑term upside as cash infusion reduces dilution concerns; long‑term price may stabilize.

Evidence & confidence

Large, primary disclosure of fresh equity financing; market typically reacts positively to secured funding for pipeline programs.

Market effects

Biotech sector may see modest uplift as a peer secures sizable financing.

US biotech financing environment reinforced.

Limited to investors focused on small‑cap biotech equities.

Counterpoint

The dilution from new shares could pressure the stock despite cash infusion.

Key entities

  • Tyra Biosciences, Inc.

    US‑listed biotech company (ticker TYRA).

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

$TYRAMedAI 8/10

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.